Effects of the protein tyrosine kinase inhibitor, SU5614, on leukemic and normal stem cells

Haematologica. 2005 Nov;90(11):1577-8.

Abstract

FLT3 activating mutations are the most frequent single genetic abnormality in patients with acute myeloid leukemia. Thus targeting the FLT3 activated kinase is a promising treatment approach. We wanted to test whether the protein tyrosine kinase inhibitor SU5614 selectively eliminates leukemic stem cells while sparing their normal counterparts.

Publication types

  • Comparative Study
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Cells, Cultured
  • Hematopoietic Stem Cells / drug effects*
  • Hematopoietic Stem Cells / enzymology*
  • Humans
  • Indoles / pharmacology*
  • Indoles / therapeutic use
  • Leukemia, Myeloid, Acute / drug therapy
  • Leukemia, Myeloid, Acute / enzymology*
  • Leukemia, Myeloid, Acute / genetics
  • Middle Aged
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Protein-Tyrosine Kinases / metabolism
  • fms-Like Tyrosine Kinase 3 / genetics

Substances

  • Indoles
  • Protein Kinase Inhibitors
  • SU 5614
  • FLT3 protein, human
  • Protein-Tyrosine Kinases
  • fms-Like Tyrosine Kinase 3